secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001867096-22-000102
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma Q2 net product revenue record $25.3M, reaffirms FY guidance
---------------------------------------------------------------------------

- Record Q2 net product revenue $25.3M, up 15% from Q1 and 34% pro forma YoY.
- Gvoke net revenue $11.5M (+30% YoY); Keveyis $12.8M (+28% pro forma); Recorlev $1.0M.
- Cash $111.6M at quarter-end; reaffirms FY net product revenue $105M-$120M, cash flow breakeven by end 2023.
- Net loss $26.2M ($0.19/sh) in Q2, $59.9M ($0.44/sh) in H1.
- Ogluo commercial partner Tetris Pharma acquired by Arecor Therapeutics in August 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000102/0001867096-22-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000102/xers-20220810.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer